(Q50052368)

English

Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers.

scientific article published in November 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/19887136

Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/19887136

Pseudomonas aeruginosa

1 reference

based on heuristic

inferred from title

author name string

Dirk Bumann

1

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/19887136

Christoph Behre

2

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/19887136

Katharina Behre

3

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/19887136

Steffen Herz

4

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/19887136

Britta Gewecke

5

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/19887136

J Engelbert Gessner

6

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/19887136

Bernd Ulrich von Specht

7

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/19887136

Ulrich Baumann

8

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/19887136

language of work or name

0 references

publication date

1 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/19887136

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/19887136

28

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/19887136

3

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/19887136

707-713

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/19887136

A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Vaccines and immunotherapy against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Plasma-cell homing

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Mucosal immunity and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Mucosal vaccination against bacterial respiratory infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Live attenuated versus inactivated influenza vaccine in infants and young children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Immunisation with non-integral OMPs promotes pulmonary clearance ofPseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Immune response mechanisms against Pseudomonas aeruginosa associated with mucosal immunization with protein antigens in a rat model of acute lung infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Outer Membrane Proteins of Pseudomonas aeruginosa Serotype Strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Immunogenic efficacy of differently produced recombinant vaccines candidates against Pseudomonas aeruginosa infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Recombinant liveSalmonellaspp. for human vaccination against heterologous pathogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Regulated antigen expression in live recombinant Salmonella enterica serovar Typhimurium strongly affects colonization capabilities and specific CD4(+)-T-cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Salmonella typhi uses CFTR to enter intestinal epithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

A comparison of immunogenicity and in vivo distribution of Salmonella enterica serovar Typhi and Typhimurium live vector vaccines delivered by mucosal routes in the murine model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.10.080

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/19887136

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/19887136

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50052368&oldid=1794595565"